Clinical Trial

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

Name: Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients — clinical trial record (NCT06908772)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

To evaluate the efficacy and safety of glumetinib combined with osimertinib as the first-line treatment for locally advanced or metastatic NSCLC.

Trial Details

NCT Number	NCT06908772
Lead Sponsor	Shanghai JMT-Bio Inc.
Conditions	Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Enrollment	390 participants
Start Date	2025-04-01
Primary Completion	2028-12-31 (estimated)
Study Completion	2030-01-31 (estimated)
Updated on ClinicalTrials.gov	2025-04-03